140 related articles for article (PubMed ID: 37093965)
1. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y
Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
Sato T; Nagai M; Watanabe O; Misu T; Takenouchi N; Ohkubo R; Ishihara S; Tsuboi Y; Katsuno M; Nakagawa M; Matsushita T; Aso Y; Matsuura E; Tokashiki T; Mukaino A; Adachi H; Nakanishi K; Yamaguchi Y; Yamaguchi S; Yamano Y
J Neurol; 2024 Jun; 271(6):3471-3485. PubMed ID: 38430272
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series.
Meyerowitz EA; Mukerji SS; Kyle Harrold G; Erdil RM; Chen ST; Rudmann EA; Tsibris A; Venna N; Robbins GK
Clin Infect Dis; 2023 Sep; 77(6):851-856. PubMed ID: 37157862
[TBL] [Abstract][Full Text] [Related]
5. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
[TBL] [Abstract][Full Text] [Related]
6. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression.
Gomes YCP; Freitas NL; Souza FS; Sandim V; Pereira DA; Nogueira FCS; Echevarria-Lima J; Leite ACCB; Lima MASD; Silva MTT; Araújo AQC; Vicente ACP; Espíndola OM
Front Immunol; 2022; 13():949516. PubMed ID: 36052089
[TBL] [Abstract][Full Text] [Related]
7. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.
Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM
Front Immunol; 2021; 12():737941. PubMed ID: 34764955
[TBL] [Abstract][Full Text] [Related]
8. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study.
de Oliveira CJV; Neto JAC; Liberato de Matos SNF; Oliveira P; Tannus M; Castro N; Rocha PN; Carvalho EM
J Sex Med; 2023 Feb; 20(3):269-276. PubMed ID: 36751985
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.
Takatani M; Crispim ME; Fraiji N; Stefani MM; Kiesslich D
Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e5. PubMed ID: 28380116
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.
Tsutsumi S; Sato T; Yagishita N; Yamauchi J; Araya N; Hasegawa D; Nagasaka M; Coler-Reilly ALG; Inoue E; Takata A; Yamano Y
Orphanet J Rare Dis; 2019 Oct; 14(1):227. PubMed ID: 31639014
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of T Regulatory Lymphocytes Transcription Factors in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Patients.
Ghezeldasht SA; Sadeghian H; Azarpazhooh MR; Shamsian SAA; Rafatpanah H; Mahmoodi M; Rezaee SA
Appl Biochem Biotechnol; 2017 Aug; 182(4):1403-1414. PubMed ID: 28101786
[TBL] [Abstract][Full Text] [Related]
12. Nanomicellar Curcumin Supplementation Improves the Clinical Manifestations of HAM/TSP Patients.
Mohammadi A; Yazdi SZ; Poursina Z; Hampson IN; Vakili V; Sahebkar A; Akbarien MM; Rahimi H; Vakili R; Boostani R; Rafatpanah H
Adv Exp Med Biol; 2021; 1328():347-359. PubMed ID: 34981488
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
Tamaki K; Sato T; Tsugawa J; Fujioka S; Yagishita N; Araya N; Yamauchi J; Coler-Reilly ALG; Nagasaka M; Hasegawa Y; Yamano Y; Tsuboi Y
Front Microbiol; 2019; 10():2110. PubMed ID: 31572323
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study.
Coler-Reilly ALG; Sato T; Matsuzaki T; Nakagawa M; Niino M; Nagai M; Nakamura T; Takenouchi N; Araya N; Yagishita N; Inoue E; Yamano Y
Neurotherapeutics; 2017 Oct; 14(4):1084-1094. PubMed ID: 28536850
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Nakamura T; Nishiura Y; Eguchi K
Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):137-49. PubMed ID: 20021347
[TBL] [Abstract][Full Text] [Related]
16. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
Gessain A; Mahieux R
Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
[TBL] [Abstract][Full Text] [Related]
17. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.
Sato T; Coler-Reilly A; Utsunomiya A; Araya N; Yagishita N; Ando H; Yamauchi J; Inoue E; Ueno T; Hasegawa Y; Nishioka K; Nakajima T; Jacobson S; Izumo S; Yamano Y
PLoS Negl Trop Dis; 2013; 7(10):e2479. PubMed ID: 24130912
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
Kodama D; Tanaka M; Matsuzaki T; Izumo K; Nakano N; Matsuura E; Saito M; Nagai M; Horiuchi M; Utsunomiya A; Takashima H; Kubota R; Izumo S
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008361. PubMed ID: 32667912
[TBL] [Abstract][Full Text] [Related]
19. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.
Casseb J; de Oliveira AC; Vergara MP; Montanheiro P; Bonasser F; Meilman Ferreira C; Smid J; Duarte AJ
J Med Virol; 2008 Mar; 80(3):392-8. PubMed ID: 18205234
[TBL] [Abstract][Full Text] [Related]
20. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression.
Olindo S; Lézin A; Cabre P; Merle H; Saint-Vil M; Edimonana Kaptue M; Signate A; Césaire R; Smadja D
J Neurol Sci; 2005 Oct; 237(1-2):53-9. PubMed ID: 15972218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
